aTYR PHARMA INC (ATYR): Capital Expenditures
$77.0K
Year ended 2025-12-31
$279.0K
Trailing 12 months to 2026-06-30
-63.9%
3-year compound annual growth
-17.5%
5-year compound annual growth
-19.4%
10-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $77.0K | +18.5% | 2026-03-05, From 2025-01-01 |
| 2024-12-31 | $65.0K | -98.5% | 2026-03-05, From 2024-01-01 |
| 2023-12-31 | $4.21M | +156.9% | 2026-03-05, From 2023-01-01 |
| 2022-12-31 | $1.64M | +754.7% | 2025-03-13, From 2022-01-01 |
| 2021-12-31 | $192.0K | -5.0% | 2024-03-14, From 2021-01-01 |
| 2020-12-31 | $202.0K | +155.7% | 2023-03-14, From 2020-01-01 |
| 2019-12-31 | $79.0K | -86.7% | 2022-03-15, From 2019-01-01 |
| 2018-12-31 | $594.0K | -54.7% | 2021-03-24, From 2018-01-01 |
| 2017-12-31 | $1.31M | +118.7% | 2020-03-26, From 2017-01-01 |
| 2016-12-31 | $600.0K | -9.6% | 2019-03-26, From 2016-01-01 |
| 2015-12-31 | $664.0K | +166.7% | 2018-03-20, From 2015-01-01 |
| 2014-12-31 | $249.0K | -61.3% | 2017-03-16, From 2014-01-01 |
| 2013-12-31 | $644.0K | n/a | 2016-03-30, From 2013-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| aTYR PHARMA INC (ATYR) | 2025-12-31 | $77.0K | +18.5% |
| VivoSim Labs, Inc. (VIVS) | 2026-03-31 | $0 | -100.0% |
| AIM ImmunoTech Inc. (AIM) | 2024-12-31 | $18.0K | n/a |
| Cardiff Oncology, Inc. (CRDF) | 2025-12-31 | $44.0K | -45.0% |
| Inmune Bio, Inc. (INMB) | 2025-12-31 | $1.04M | n/a |
| Entera Bio Ltd. (ENTX) | 2025-12-31 | $107.0K | n/m |
| Prokidney Corp. (PROK) | 2025-12-31 | $15.20M | -48.5% |
| Pluri Inc. (PLUR) | 2026-06-30 | $633.0K | -60.9% |
| Inhibrx Biosciences, Inc. (INBX) | 2025-12-31 | $31.0K | -98.8% |
Compare ATYR, VIVS, AIM, CRDF side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗